Literature DB >> 15762191

Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck paragangliomas.

W H van Houtum1, E P M Corssmit, P B Douwes Dekker, J C Jansen, A G L van der Mey, A H J T Bröcker-Vriends, P E M Taschner, M Losekoot, M Frölich, M P M Stokkel, C J Cornelisse, J A Romijn.   

Abstract

OBJECTIVE: The aim of this study was to identify the prevalence of catecholamine excess and phaeochromocytomas in a well-defined population of people with hereditary head and neck paragangliomas.
METHODS: We studied in a prospective follow-up protocol all consecutive patients referred to the Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands with documented head and neck paragangliomas and either a positive family history for paragangliomas or a proven SDHD gene mutation. Initial analysis included medical history, physical examination and the measurement of excretion of catecholamines in two 24-h urine collections. In the case of documented catecholamine excess iodinated meta-iodobenzylguanidine (123I-MIBG) scintigraphy and magnetic resonance imaging were done.
RESULTS: Between 1988 and 2003, 40 consecutive patients (20 male and 20 female) with documented head and neck paragangliomas were screened. Biochemical screening revealed urinary catecholamine excess in 15 patients (37.5%). In nine of these 15 patients a lesion was found by 123I-MIBG scintigraphy. Exact localization by magnetic resonance imaging revealed phaeochromocytomas in seven of the 15 patients. One of the nine patients had an extra-adrenal paraganglioma. Histopathological examination in a subset of tumors displayed loss of heterozygosity of the wild-type SDHD allele in all cases.
CONCLUSIONS: The prevalence of catecholamine excess (37.5%) and phaeochromocytomas (20.0%) is high in patients with familial head and neck paragangliomas. Therefore, patients with hereditary head and neck paragangliomas require lifelong follow up by biochemical testing for catecholamine excess.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15762191     DOI: 10.1530/eje.1.01833

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  11 in total

1.  Catecholamine-secreting paragangliomas: recent progress in diagnosis and perioperative management.

Authors:  Tahl Y Colen; Frederick G Mihm; Theodore P Mason; Joseph B Roberson
Journal:  Skull Base       Date:  2009-11

2.  Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior.

Authors:  Hans K Ghayee; Bas Havekes; Eleonora P M Corssmit; Graeme Eisenhofer; Stephen R Hammes; Zahid Ahmad; Alexander Tessnow; Ivica Lazúrová; Karen T Adams; Antonio T Fojo; Karel Pacak; Richard J Auchus
Journal:  Endocr Relat Cancer       Date:  2008-12-15       Impact factor: 5.678

Review 3.  Update on pediatric pheochromocytoma.

Authors:  Bas Havekes; Johannes A Romijn; Graeme Eisenhofer; Karen Adams; Karel Pacak
Journal:  Pediatr Nephrol       Date:  2008-06-20       Impact factor: 3.714

4.  Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma.

Authors:  Edwin W Lai; Shiromi M Perera; Bas Havekes; Henri J L M Timmers; Frederieke M Brouwers; Beverly McElroy; Karen T Adams; Shoichiro Ohta; Robert A Wesley; Graeme Eisenhofer; Karel Pacak
Journal:  Endocrine       Date:  2008-11-04       Impact factor: 3.633

5.  Low penetrance of a SDHB mutation in a large Dutch paraganglioma family.

Authors:  Frederik J Hes; Marjan M Weiss; Sanne A Woortman; Noel F de Miranda; Patrick A van Bunderen; Bert A Bonsing; Marcel P M Stokkel; Hans Morreau; Johannes A Romijn; Jeroen C Jansen; Annette H J T Vriends; Jean-Pierre L Bayley; Eleonora P M Corssmit
Journal:  BMC Med Genet       Date:  2010-06-11       Impact factor: 2.103

6.  Familial paragangliomas.

Authors:  Cjm Lips; Egwm Lentjes; Jwm Höppener; Rb van der Luijt; Fl Moll
Journal:  Hered Cancer Clin Pract       Date:  2006-10-15       Impact factor: 2.857

7.  The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family.

Authors:  Erik F Hensen; Jeroen C Jansen; Maaike D Siemers; Jan C Oosterwijk; Annette Hjt Vriends; Eleonora Pm Corssmit; Jean-Pierre Bayley; Andel Gl van der Mey; Cees J Cornelisse; Peter Devilee
Journal:  Eur J Hum Genet       Date:  2010-01       Impact factor: 4.246

Review 8.  SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes.

Authors:  B Pasini; C A Stratakis
Journal:  J Intern Med       Date:  2009-07       Impact factor: 8.989

9.  Head-and-neck paragangliomas are associated with sleep-related complaints, especially in the presence of carotid body tumors.

Authors:  Bas Havekes; Florine Kastelein; Agatha A van der Klaauw; Nicolette van Duinen; Jeroen C Jansen; Jan W A Smit; Klaas W van Kralingen; Annette H J T Vriends; Johannes A Romijn; Eleonora P M Corssmit
Journal:  Sleep Breath       Date:  2011-05-27       Impact factor: 2.816

10.  Similar gene expression profiles of sporadic, PGL2-, and SDHD-linked paragangliomas suggest a common pathway to tumorigenesis.

Authors:  Erik F Hensen; Jelle J Goeman; Jan Oosting; Andel G L Van der Mey; Pancras C W Hogendoorn; Cor W R J Cremers; Peter Devilee; Cees J Cornelisse
Journal:  BMC Med Genomics       Date:  2009-05-11       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.